TY - JOUR
AU - A. Cohen
AU - C. Wallenhorst
AU - M. Rivera
AU - C. Ay
AU - B. Schaefer
AU - K. Abdelgawwad
AU - G. Psaroudakis
AU - G. Brobert
AU - A. Ekbom
AU - A. Y. Y. Lee
AU - A. Khorana
AU - C. Becattini
AU - M. Carrier
AU - C. Coleman
AU - C. Martinez
AD - Department of Haematolgy, Guy's and St Thomas' Hospitals NHS Trust, London, United Kingdom of Great Britain and Northern Ireland.
Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt, Germany.
(at time of study conduct), Bayer AG, Berlin, Germany.
Research and Development, Janssen, Barcelona, Spain.
Department of Medicine I, Clinical Division of Haematology and Haemostaseology, Medical University Vienna, Vienna, Austria.
Consultant, Bayer Pharma AG, Berlin, Germany.
Thrombosis and Opthalmology, Bayer Pharma AG Pharmaforschungszentrum Wuppertal, Berlin, Germany.
Bayer Pharma AG, Berlin, Germany.
Unit of Clinical Epidemiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
The University of British Columbia, Vancouver, Canada.
Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, United States.
Internal and Cardiovascular Medicine,Department of Internal Medicine, University of Perugia, Perugia, Italy.
Department of Medicine. University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Canada.
School of Pharmacy, University of Connecticut, Hartford, United States.
AN - 38301711
BT - Thromb Haemost
DO - 10.1055/a-2259-0662
DP - NLM
ET - 2024/02/02
LA - eng
N1 - 2567-689x
Cohen, Alexander
Wallenhorst, Christopher
Orcid: 0000-0001-7944-7347
Rivera, Marcela
Ay, Cihan
Schaefer, Bernhard
Abdelgawwad, Khaled
Psaroudakis, George
Brobert, Gunnar
Ekbom, Anders
Lee, Agnes Y Y
Khorana, Alok A
Orcid: 0000-0002-9509-0998
Becattini, Cecilia
Carrier, Marc
Coleman, Craig I
Orcid: 0000-0003-4868-7158
Martinez, Carlos
Orcid: 0000-0001-6498-6428
Clinical Trial
Germany
Thromb Haemost. 2024 Feb 1. doi: 10.1055/a-2259-0662.
PY - 2024
SN - 0340-6245
T2 - Thromb Haemost
TI - Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low Molecular Weight Heparin - The OSCAR-UK Study
ER -